Intended for healthcare professionals


Gliflozins and reducing cardiovascular events . . . and other stories

BMJ 2017; 357 doi: (Published 07 June 2017) Cite this as: BMJ 2017;357:j2677

Gliflozins and cardiovascular protection

Plenty of drugs lower blood glucose in people with type 2 diabetes, and produce millions in revenue for their manufacturers. But it came as a surprise even to the trialists when one drug, empagliflozin, produced a clear signal of benefit in reducing cardiovascular events as well as sugar (Circulation doi:10.1161/CIRCULATIONAHA.117.029190). Most trials of other drugs in the sodium-glucose co-transporter-2 inhibitor (SGLT-2i) class were not powered to show a similar effect, but an observational study based on registry data from more than 300 000 patients in Europe and the United States suggests a reduction in heart failure and cardiovascular death from all drugs in the SGLT-2i class.

Parent delivered CBT for anxious kids

Mental health services for …

View Full Text

Log in

Log in through your institution


* For online subscription